Total Payments
$257,471
2024 Payments
$35,121
Companies
13
Transactions
154
Medicare Patients
2,949
Medicare Billing
$2.5M
Payment Breakdown by Category
Consulting$139,333 (54.1%)
Research$81,449 (31.6%)
Other$19,658 (7.6%)
Travel$13,571 (5.3%)
Food & Beverage$3,460 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $139,333 | 42 | 54.1% |
| Unspecified | $81,449 | 30 | 31.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,658 | 17 | 7.6% |
| Travel and Lodging | $13,571 | 30 | 5.3% |
| Food and Beverage | $3,460 | 35 | 1.3% |
Payments by Type
General
$176,022
124 transactions
Research
$81,449
30 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $116,529 | 54 | $0 (2024) |
| Genentech, Inc. | $78,301 | 33 | $0 (2024) |
| Merck Sharp & Dohme LLC | $36,705 | 43 | $0 (2022) |
| Alimera Sciences, Inc. | $6,766 | 1 | $0 (2017) |
| Regeneron Pharmaceuticals, Inc. | $4,831 | 3 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $4,750 | 1 | $0 (2023) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $2,469 | 3 | $0 (2020) |
| Daiichi Sankyo Company LTD | $2,305 | 3 | $0 (2020) |
| Janssen Research & Development, LLC | $2,125 | 4 | $0 (2022) |
| Allergan, Inc. | $1,567 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35,121 | 18 | F. Hoffmann-La Roche AG ($33,441) |
| 2023 | $9,991 | 4 | Regeneron Pharmaceuticals, Inc. ($4,761) |
| 2022 | $15,748 | 18 | Merck Sharp & Dohme LLC ($11,813) |
| 2021 | $34,256 | 11 | F. Hoffmann-La Roche AG ($28,264) |
| 2020 | $21,967 | 19 | F. Hoffmann-La Roche AG ($12,394) |
| 2019 | $52,880 | 40 | F. Hoffmann-La Roche AG ($32,511) |
| 2018 | $72,042 | 29 | Genentech, Inc. ($57,441) |
| 2017 | $15,465 | 15 | Alimera Sciences, Inc. ($6,766) |
All Payment Transactions
154 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $602.09 | Research |
| Study: Mitigation of endoph: Surgical evolution • Category: Ophthalmology | ||||||
| 10/10/2024 | Genentech, Inc. | Lucentis (Biological) | Consulting Fee | Cash or cash equivalent | $1,680.00 | General |
| Category: Ophthalmology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $828.62 | Research |
| Study: Technical Updates to Port Delivery System With Ranibizumab (PDS) and Clinical Experience With Updated Refill Needle • Category: Ophthalmology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $689.33 | Research |
| Study: Technical Updates to Port Delivery System With Ranibizumab (PDS) for the Treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) • Category: Ophthalmology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $689.33 | Research |
| Study: Technical Updates to Port Delivery System With Ranibizumab (PDS) and Clinical Experience With Updated Refill Needle • Category: Ophthalmology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $480.00 | Research |
| Study: Clinical Impact of the Port Delivery System With Ranibizumab (PDS) in Retinal Diseases • Category: Ophthalmology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $280.83 | Research |
| Study: Technical Updates to Port Delivery System With Ranibizumab (PDS) for the Treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) • Category: Ophthalmology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $2,623.08 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $1,377.08 | Research |
| Study: Port Delivery System of Ranibizumab Extension Study • Category: Ophthalmology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $919.11 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $723.08 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $259.23 | Research |
| Study: Technical Updates to the Port Delivery System With Ranibizumab for the Treatment of Neovascular Age-Related Macular Degeneration Diabetic Macular Edema and Diabetic Retinopathy • Category: Ophthalmology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $18,444.00 | Research |
| Study: The Impact of Continuous Delivery of Ranibizumab With PDS on Retinal Nonperfusion in Diabetic Retinal Disease • Category: Ophthalmology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $3,288.60 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $1,040.27 | Research |
| Study: The Return of PDS: Port Delivery System with Ranibizumab Is Back To Enable Continuous Delivery Of Anti-VEGF Therapy For Patients with nAMD DME and DR • Category: Ophthalmology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $588.85 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $374.44 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $233.33 | Research |
| Study: Technical Updates to Port Delivery System With Ranibizumab (PDS) and Clinical Experience With Updated Refill Needle • Category: Ophthalmology | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $479.55 | Research |
| Study: The Return of PDS: Port Delivery System with Ranibizumab Is Back To Enable Continuous Delivery Of Anti-VEGF Therapy For Patients with nAMD, DME, and DR • Category: Ophthalmology | ||||||
| 08/25/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $3,703.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/25/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $1,058.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/09/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,750.00 | General |
| 09/30/2022 | Genentech, Inc. | Lucentis (Biological), SUSVIMO, VABYSMO | Food and Beverage | In-kind items and services | $31.64 | General |
| Category: Ophthalmology | ||||||
| 09/01/2022 | Roche Products Limited | SUSVIMO (Drug), VABYSMO | Food and Beverage | In-kind items and services | $98.91 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/30/2022 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $1,604.17 | Research |
| Study: HETEROGENEITY AMONG PATIENTS WITH RETINAL VEIN OCCLUSION RELATIONSHIP BETWEEN INJECTION NEED AND VISION OUTCOMES WITH AS-NEEDED RANIBIZUMAB • Category: Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PDS PHASE 3 ARCHWAY | F. Hoffmann-La Roche AG | $28,264 | 4 |
| The Impact of Continuous Delivery of Ranibizumab With PDS on Retinal Nonperfusion in Diabetic Retinal Disease | F. Hoffmann-La Roche AG | $18,444 | 1 |
| STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | F. Hoffmann-La Roche AG | $8,517 | 6 |
| PALADIN | Alimera Sciences, Inc. | $6,766 | 1 |
| PDS phase 3 ARCHWAY | F. Hoffmann-La Roche AG | $4,929 | 2 |
| A PHASE II MULTICENTER, RANDOMIZED, ACTIVE TREATMENT-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF THE RANIBIZUMAB PORT DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF RANIBIZUMAB IN PATIENTS WITH SUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | F. Hoffmann-La Roche AG | $3,490 | 2 |
| Clinical Trial Versus Real-World Outcomes With Anti-Vascular Endothelial Growth Factor Therapy for Central Retinal Vein Occlusion | F. Hoffmann-La Roche AG | $2,476 | 2 |
| Technical Updates to Port Delivery System With Ranibizumab (PDS) and Clinical Experience With Updated Refill Needle | F. Hoffmann-La Roche AG | $1,751 | 3 |
| HETEROGENEITY AMONG PATIENTS WITH RETINAL VEIN OCCLUSION RELATIONSHIP BETWEEN INJECTION NEED AND VISION OUTCOMES WITH AS-NEEDED RANIBIZUMAB | F. Hoffmann-La Roche AG | $1,604 | 1 |
| Port Delivery System of Ranibizumab Extension Study | F. Hoffmann-La Roche AG | $1,377 | 1 |
| The Return of PDS: Port Delivery System with Ranibizumab Is Back To Enable Continuous Delivery Of Anti-VEGF Therapy For Patients with nAMD DME and DR | F. Hoffmann-La Roche AG | $1,040 | 1 |
| Technical Updates to Port Delivery System With Ranibizumab (PDS) for the Treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) | F. Hoffmann-La Roche AG | $970.16 | 2 |
| Mitigation of endoph: Surgical evolution | F. Hoffmann-La Roche AG | $602.09 | 1 |
| Clinical Impact of the Port Delivery System With Ranibizumab (PDS) in Retinal Diseases | F. Hoffmann-La Roche AG | $480.00 | 1 |
| The Return of PDS: Port Delivery System with Ranibizumab Is Back To Enable Continuous Delivery Of Anti-VEGF Therapy For Patients with nAMD, DME, and DR | F. Hoffmann-La Roche AG | $479.55 | 1 |
| Technical Updates to the Port Delivery System With Ranibizumab for the Treatment of Neovascular Age-Related Macular Degeneration Diabetic Macular Edema and Diabetic Retinopathy | F. Hoffmann-La Roche AG | $259.23 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 717 | 1,991 | $1.3M | $482,007 |
| 2022 | 11 | 807 | 2,598 | $1.7M | $646,773 |
| 2021 | 13 | 825 | 2,347 | $1.7M | $701,178 |
| 2020 | 7 | 600 | 1,972 | $1.7M | $707,224 |
Total Patients
2,949
Total Services
8,908
Medicare Billing
$2.5M
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 63 | 584 | $876,000 | $398,138 | 45.4% |
| 67028 | Injection of drug into eye | Office | 2023 | 90 | 349 | $248,825 | $35,384 | 14.2% |
| 92134 | Imaging of retina | Office | 2023 | 297 | 690 | $115,716 | $21,571 | 18.6% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 217 | 317 | $67,371 | $21,357 | 31.7% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 22 | 22 | $6,862 | $2,250 | 32.8% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 14 | 14 | $5,844 | $1,669 | 28.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 14 | 15 | $6,672 | $1,639 | 24.6% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 64 | 692 | $1.0M | $494,427 | 47.6% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2022 | 12 | 273 | $96,096 | $42,497 | 44.2% |
| 67028 | Injection of drug into eye | Office | 2022 | 83 | 378 | $249,795 | $39,690 | 15.9% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 252 | 384 | $72,552 | $26,041 | 35.9% |
| 92134 | Imaging of retina | Office | 2022 | 305 | 761 | $114,150 | $24,646 | 21.6% |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2022 | 11 | 11 | $55,000 | $10,730 | 19.5% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 18 | 18 | $7,380 | $2,197 | 29.8% |
| J7999 | Compounded drug, not otherwise classified | Office | 2022 | 14 | 33 | $4,125 | $2,161 | 52.4% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 17 | 17 | $4,607 | $1,737 | 37.7% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 16 | 16 | $6,424 | $1,664 | 25.9% |
| 92002 | New patient problem focused exam of visual system | Office | 2022 | 15 | 15 | $3,066 | $982.83 | 32.1% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 57 | 822 | $1.2M | $599,310 | 48.6% |
| 67028 | Injection of drug into eye | Office | 2021 | 82 | 404 | $281,385 | $45,155 | 16.0% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2021 | 225 | 303 | $55,752 | $21,741 | 39.0% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 313 | 627 | $94,050 | $21,224 | 22.6% |
| J7999 | Compounded drug, not otherwise classified | Office | 2021 | 20 | 56 | $7,000 | $3,717 | 53.1% |
| 92002 | Eye and medical examination for diagnosis and treatment, new patient | Office | 2021 | 30 | 30 | $6,181 | $2,123 | 34.4% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Office | 2021 | 16 | 16 | $6,560 | $2,030 | 31.0% |
About Dr. Peter Campochiaro, M.D
Dr. Peter Campochiaro, M.D is a Ophthalmology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1598723850.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Campochiaro, M.D has received a total of $257,471 in payments from pharmaceutical and medical device companies, with $35,121 received in 2024. These payments were reported across 154 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($139,333).
As a Medicare-enrolled provider, Campochiaro has provided services to 2,949 Medicare beneficiaries, totaling 8,908 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Baltimore, MD
- Active Since 05/03/2006
- Last Updated 12/12/2012
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1598723850
Products in Payments
- Lucentis (Biological) $125,548
- Non-Covered Product (Drug) $67,897
- ILUVIEN (Biological) $6,766
- EYLEA (Biological) $4,761
- MK-8931 (Drug) $2,650
- XIPERE (Drug) $2,469
- SUSVIMO (Drug) $98.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Baltimore
Dr. Alfred Sommer, M.d, M.D
Ophthalmology — Payments: $3.7M
Ophthalmology $3.7M
Peter Mcdonnell
Ophthalmology — Payments: $2.2M
Ophthalmology $2.2M
Esen Akpek, M.d, M.D
Ophthalmology — Payments: $627,113
Ophthalmology $627,113
Neil Bressler, M.d, M.D
Ophthalmology — Payments: $524,415
Ophthalmology $524,415
Jennifer Thorne, M.d, M.D
Ophthalmology — Payments: $201,745
Ophthalmology $201,745
Dr. Earl Craven, Md, MD
Ophthalmology — Payments: $187,007
Ophthalmology $187,007